- 询价
- 2026年09月03日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
AI 赋能培养基定制开发：CHO 培养基是如何实现产量提升Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 细胞形态：
上皮样
- 器官来源：
其他
- 生长状态：
贴壁生长
- 年限：
53 years
- 物种来源：
人
- 是否是肿瘤细胞：
0
- 相关疾病：
腺癌
- ATCC Number：
HTB-40™
- 库存：
大量
- 运输方式：
冻存运输
| Designations: | HuTu 80 | ||
| Depositors: | V Larson | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | adherent | ||
| Organism: | Homo sapiens | ||
| Morphology: | epithelial |
||
| Source: | Organ: duodenum Disease: adenocarcinoma |
||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Receptors: | bombesin | ||
| Tumorigenic: | Yes | ||
| Antigen Expression: | Blood Type B; Rh+ | ||
| DNA Profile (STR): | Amelogenin: X,Y CSF1PO: 11,13 D13S317: 8,11 D16S539: 10,11 D5S818: 12,13 D7S820: 9,11 THO1: 7 TPOX: 9,11 vWA: 16,18 |
||
| Cytogenetic Analysis: | modal number = 46; range = 42 to 48. This is a pseudodiploid human cell line. The modal chromosome number is 46 occurring at 68% and polyploidy at 0.4%. Three marker chromosomes were detected in all metaphases examined. Two markers that appeared to be the product of the balanced translocation between N1 and N17. The third marker is ?inv(13). No other common markers were detected. Normal N1, N13, and N17 had single-copy each. Y chromosome is present. |
||
| Isoenzymes: | AK-1, 1 ES-D, 1 G6PD, B GLO-I, 2 Me-2, 2 PGM1, 1-2 PGM3, 1-2 |
||
| Age: | 53 years | ||
| Gender: | male | ||
| Ethnicity: | Caucasian | ||
| Comments: | The cells express receptors for bombesin at up to 6000 sites per cell. | ||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C |
||
| Subculturing: | Protocol:
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:5 is recommended Medium Renewal: 2 to 3 times per week |
||
| Preservation: | Freeze medium: Complete growth medium, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003 recommended serum:ATCC 30-2020 |
||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验ScFv表达载体pFUW80的基因图谱 由于单链抗体可以在大肠杆菌中正确装配、表达，而抗体片段在大肠杆菌中的表达具有规模大、速度快和成本低的优点，目前主要利用原核的大肠杆菌表达载体表达单链抗体。 单链抗体基因的设计应设计理想的连接序列(linker)，以保证VH和VL在表达系统中能等摩尔地产生，不干扰VH和VL的自由折叠，并使抗原结合位点处于适当构型，不引起分子动力学改变，尽可能减少蛋白酶攻击及防止单链抗体聚集等。目前最常用的连接序列为具
CD80 分子 CD80 常用单克隆抗体或代号： B7- 1,BB1 主要表达细胞： Ba,Mac,TStr [B] 分子质量(kDa)和结构： gp60(IgSF) 功 能： 活化B细胞抗原,CD28、CTLA- 4配体,提供T细胞共刺激信号 CD80 Aka B7-1, BB1 Ligand for T cell marker CD28 or CTLA4 (CD152
恢复 80% 头发生长！首个治疗斑秃的口服脱发新药在中国获批上市
者进展为全秃或普秃。重度斑秃顽固、难治、易复发，且严重影响患者的心理健康和生活质量，既往治疗基本上口服和外用激素，虽然有一定疗效，但是也有很多副作用，多数患者对治疗不满意。 巴瑞替尼是一款每日口服一次的 JAK 抑制剂，有 4 mg、2 mg 和 1 mg 三种剂量。作为国内首个且唯一用于系统性治疗重度斑秃的创新靶向药物，可帮助患者获得显著的毛发再生，对头发、眉毛、睫毛等区域具有持续性的显著改善作用。 NEJM 两项 III 期临床数据证实，可使 80% 头发恢复生长 2022 年
技术资料暂无技术资料 索取技术资料
